Referred to the Committee on Armed Services, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The Defense Biotechnology Strategy Act directs the Department of Defense to develop a comprehensive strategy within one year addressing how emerging biotechnologies affect national security and military capabilities. The strategy must cover expanding domestic biomanufacturing facilities for defense needs, updating military standards to incorporate biotech products, establishing purchase agreements for defense-related biotech, and integrating biotechnology into military planning exercises. The bill also requires the Defense Department to evaluate research initiatives to make biotechnology more predictable and engineerable, develop regulatory tools and digital infrastructure to speed biotech adoption, and coordinate with NATO allies to pool resources and share research capabilities in biotechnology development. The legislation affects the Defense Department and its contractors, along with international partners, but does not specify new funding amounts or appropriations. By requiring this strategy, Congress aims to ensure the U.S. military can effectively leverage biotechnology advances while strengthening international cooperation on defense-related biotech innovation.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.